Javascript must be enabled to continue!
610. Tele-ID Consult Services at Academic Medical Centers: Experience and Outcomes During the SARS-CoV-2 Pandemic
View through CrossRef
Abstract
Background
Remote telemedicine ID consults (Tele-ID) appear to be effective for inpatients at community hospitals. Tele-ID is not used at academic medical centers (AMCs) because of the availability of onsite ID physicians. During the COVID-19 pandemic, intra-hospital Tele-ID was implemented because of insufficient PPE and the risk of SARS-CoV-2 exposure. To understand the effectiveness of intra-hospital Tele-ID, we compared outcomes following Tele vs. in-person ID consultation.
Methods
This is a longitudinal, matched, case-control study at two tertiary AMCs in Pittsburgh. Cases were evaluated via Tele-ID only (video, e-consults +/- inpatient phone call) between 3/1/20 – 5/31/20. Controls had in-person consults between 3/1/19 – 11/30/19 matched to cases by sex, race, ethnicity, transplant, age, BMI, Elixhauser score, and ID-specific coded diagnosis. Both groups were evaluated by existing general ID (GID) or transplant ID (TID) service physicians. Patients with COVID-19 diagnosis were excluded. Outcomes included ICU admission, hospital and ICU length of stay (LOS), in-hospital, 30 and 60-day mortality, and 30 and 60-day readmission.
Results
Among the Tele-ID group, 125 inpatients were evaluated by GID and 81 by TID. The majority were Caucasian, male, and non-ICU (Table 1). A broad range of ID diagnosis were made, most commonly bacteremia and pneumonia (Fig 1). Average hospital LOS post-ID consult was 6.26 days (GID) and 6.5 days (TID). For ICU patients, average LOS was 12 days (GID) and 7.6 days (TID). There were 5 (4%) and 3 (3.7%) in-hospital deaths, and 3 (2.4%) and 5 (6.2%) deaths at 30 days for GID and TID, respectively (Table 1). 65 cases could be matched to 633 controls by exact ID coded diagnosis (Table 2). Comparison of Tele-ID cases to in-person controls showed shorter ICU LOS (118.1 vs 269.2 hours; p = 0.002) and lower 30-day readmission (5.1 vs 17.3%; p = 0.004) for cases (Table 2). ICU admission and mortality were similar.
Conclusion
During the pandemic, intra-hospital Tele-ID proved to be an effective alternative to in-person ID consults at large AMCs, as evidenced by shorter ICU LOS and lower 30-day readmission for Tele-ID, and no difference in mortality. This experience suggests that Tele-ID could be used at AMCs as an alternative to in-person consults in non-pandemic settings.
Disclosures
Rima Abdel-Massih, MD, Infectious Disease Connect (Employee, Director of Clinical Operations) Rima Abdel-Massih, MD, Infectious Disease Connect (Individual(s) Involved: Self): Chief Medical Officer, Other Financial or Material Support, Other Financial or Material Support, Shareholder John Mellors, MD, Abound Bio, Inc. (Shareholder)Accelevir (Consultant)Co-Crystal Pharma, Inc. (Other Financial or Material Support, Share Options)Gilead Sciences, Inc. (Advisor or Review Panel member, Research Grant or Support)Infectious DIseases Connect (Other Financial or Material Support, Share Options)Janssen (Consultant)Merck (Consultant)
Oxford University Press (OUP)
Title: 610. Tele-ID Consult Services at Academic Medical Centers: Experience and Outcomes During the SARS-CoV-2 Pandemic
Description:
Abstract
Background
Remote telemedicine ID consults (Tele-ID) appear to be effective for inpatients at community hospitals.
Tele-ID is not used at academic medical centers (AMCs) because of the availability of onsite ID physicians.
During the COVID-19 pandemic, intra-hospital Tele-ID was implemented because of insufficient PPE and the risk of SARS-CoV-2 exposure.
To understand the effectiveness of intra-hospital Tele-ID, we compared outcomes following Tele vs.
in-person ID consultation.
Methods
This is a longitudinal, matched, case-control study at two tertiary AMCs in Pittsburgh.
Cases were evaluated via Tele-ID only (video, e-consults +/- inpatient phone call) between 3/1/20 – 5/31/20.
Controls had in-person consults between 3/1/19 – 11/30/19 matched to cases by sex, race, ethnicity, transplant, age, BMI, Elixhauser score, and ID-specific coded diagnosis.
Both groups were evaluated by existing general ID (GID) or transplant ID (TID) service physicians.
Patients with COVID-19 diagnosis were excluded.
Outcomes included ICU admission, hospital and ICU length of stay (LOS), in-hospital, 30 and 60-day mortality, and 30 and 60-day readmission.
Results
Among the Tele-ID group, 125 inpatients were evaluated by GID and 81 by TID.
The majority were Caucasian, male, and non-ICU (Table 1).
A broad range of ID diagnosis were made, most commonly bacteremia and pneumonia (Fig 1).
Average hospital LOS post-ID consult was 6.
26 days (GID) and 6.
5 days (TID).
For ICU patients, average LOS was 12 days (GID) and 7.
6 days (TID).
There were 5 (4%) and 3 (3.
7%) in-hospital deaths, and 3 (2.
4%) and 5 (6.
2%) deaths at 30 days for GID and TID, respectively (Table 1).
65 cases could be matched to 633 controls by exact ID coded diagnosis (Table 2).
Comparison of Tele-ID cases to in-person controls showed shorter ICU LOS (118.
1 vs 269.
2 hours; p = 0.
002) and lower 30-day readmission (5.
1 vs 17.
3%; p = 0.
004) for cases (Table 2).
ICU admission and mortality were similar.
Conclusion
During the pandemic, intra-hospital Tele-ID proved to be an effective alternative to in-person ID consults at large AMCs, as evidenced by shorter ICU LOS and lower 30-day readmission for Tele-ID, and no difference in mortality.
This experience suggests that Tele-ID could be used at AMCs as an alternative to in-person consults in non-pandemic settings.
Disclosures
Rima Abdel-Massih, MD, Infectious Disease Connect (Employee, Director of Clinical Operations) Rima Abdel-Massih, MD, Infectious Disease Connect (Individual(s) Involved: Self): Chief Medical Officer, Other Financial or Material Support, Other Financial or Material Support, Shareholder John Mellors, MD, Abound Bio, Inc.
(Shareholder)Accelevir (Consultant)Co-Crystal Pharma, Inc.
(Other Financial or Material Support, Share Options)Gilead Sciences, Inc.
(Advisor or Review Panel member, Research Grant or Support)Infectious DIseases Connect (Other Financial or Material Support, Share Options)Janssen (Consultant)Merck (Consultant).
Related Results
The Potential of Medicinal Plants and Bioactive Compounds in the Fight Against COVID-19
The Potential of Medicinal Plants and Bioactive Compounds in the Fight Against COVID-19
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a novel coronavirus , is causing a serious worldwide COVID-19 pandemic. The emergence of strains with rapid spread and...
The Hidden Problem of Cross-Reactivity: Challenges in HIV Testing During the COVID-19 Era: A Systematic Review
The Hidden Problem of Cross-Reactivity: Challenges in HIV Testing During the COVID-19 Era: A Systematic Review
Abstract
Introduction
Human immunodeficiency virus (HIV) and Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV2) surface glycoproteins, including shared epitope motifs, sho...
Kinetics of the humoral immune response to SARS-CoV-2: comparative analytical performance of seven commercial serology tests
Kinetics of the humoral immune response to SARS-CoV-2: comparative analytical performance of seven commercial serology tests
Abstract
Background
SARS-CoV-2 serology tests are clinically useful to document a prior SARS-CoV-2 infection in patients with n...
TELE-ICU BERMANFAAT DALAM PENCAPAIAN PELAYANAN BERKUALITAS
TELE-ICU BERMANFAAT DALAM PENCAPAIAN PELAYANAN BERKUALITAS
ABSTRAKKejadian mortalitas di ruang ICU masih tinggi. Pasien kritis membutuhkan perawatan kompleks sehingga membutuhkan perawat terlatih dan kompeten tetapi penyebaran tenaga masih...
Mutations in SARS-CoV
Mutations in SARS-CoV
The coronavirus family is named for the large spike protein molecules found
on the pathogen exterior, which give the virus a crown-like appearance, the coronavirus
genome is the bi...
From SARS and MERS CoVs to SARS‐CoV‐2: Moving toward more biased codon usage in viral structural and nonstructural genes
From SARS and MERS CoVs to SARS‐CoV‐2: Moving toward more biased codon usage in viral structural and nonstructural genes
AbstractBackgroundSevere acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) is an emerging disease with fatal outcomes. In this study, a fundamental knowledge gap question is to...
Performance characteristics of the VIDAS® SARS-COV-2 IgM and IgG serological assays
Performance characteristics of the VIDAS® SARS-COV-2 IgM and IgG serological assays
ABSTRACTThe COVID-19 pandemic, caused by the new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), continues to spread worldwide. Serological testing for SARS-CoV-2-spe...
P-003 Impact of SARS-CoV-2 infection on circulating male sex hormones and human semen quality: a systematic review and meta-analysis
P-003 Impact of SARS-CoV-2 infection on circulating male sex hormones and human semen quality: a systematic review and meta-analysis
Abstract
Study question
Does SARS-CoV-2 infection alter human male sex steroid hormones and semen quality?
...

